{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Osman SOS"],"funding":["prostate cancer uk","r&d division of the public health agency","Prostate Cancer UK","Public Health Agency","r&d division of the public health agency"],"pagination":["38"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8862253"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["Purpose
Boosting dominant intra-prostatic lesions (DILs) has the potential to increase the therapeutic ratio in prostate cancer radiotherapy. In this study, employing 5-fraction stereotactic ablative radiotherapy (SABR) volumetric modulated arc therapy (VMAT) to deliver 40 Gy to the prostate clinical target volume (CTV) while boosting the DIL up to 50 Gy was evaluated for patients before and after rectal spacer insertion.Materials and methods
24 Computed Tomography (CT) scans of 12 prostate cancer patients with unfavourable intermediate or high risk prostate cancer were employed in this study. At least two treatment plans were generated for each patient to compare pre- and post-spacer insertion plans. Plans were evaluated for target coverage, organs-at-risk doses, and the a"],"journal":["Radiation oncology (London, England)"],"pubmed_title":["Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers."],"pmcid":["PMC8862253"],"funding_grant_id":["MA-CE018-002","COM/4965/14"],"pubmed_authors":["Jain S","Lundy GS","Wesselman R","Hounsell AR","Irvine D","Whitten G","McGarry CK","Osman SOS","Fairmichael C","Wilson ML","Prise KM"],"additional_accession":[]},"is_claimable":false,"name":"Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers.","description":"Purpose
Boosting dominant intra-prostatic lesions (DILs) has the potential to increase the therapeutic ratio in prostate cancer radiotherapy. In this study, employing 5-fraction stereotactic ablative radiotherapy (SABR) volumetric modulated arc therapy (VMAT) to deliver 40 Gy to the prostate clinical target volume (CTV) while boosting the DIL up to 50 Gy was evaluated for patients before and after rectal spacer insertion.Materials and methods
24 Computed Tomography (CT) scans of 12 prostate cancer patients with unfavourable intermediate or high risk prostate cancer were employed in this study. At least two treatment plans were generated for each patient to compare pre- and post-spacer insertion plans. Plans were evaluated for target coverage, organs-at-risk doses, and the a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-31T22:48:00.345Z","creation":"2025-04-04T19:30:38.826Z"},"accession":"S-EPMC8862253","cross_references":{"pubmed":["35193630"],"doi":["10.1186/s13014-022-02003-8"]}}